Moderna, Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Moderna, Inc. (MRNA) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-20.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-02-20
- Moderna, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2020-12-31 was -$107.00K, a 101.49% decline year-over-year.
- Moderna, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2020-09-30 was $1.09M, a 88.41% decline year-over-year.
- Moderna, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2020-06-30 was $0.00.
- Moderna, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2020-03-31 was $16.02M, a 8.04% decline year-over-year.
- Moderna, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Moderna, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $100.00M, a 85.99% decline from fiscal 2023.
- Moderna, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $714.00M, a 3470.00% increase from fiscal 2022.
- Moderna, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $20.00M, a 72.22% decline from fiscal 2021.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-20 | ||||
| 2024-12-31 | $100.00M 10-K · filed 2026-02-20 | ||||
| 2023-12-31 | $714.00M 10-K · filed 2026-02-20 | ||||
| 2022-12-31 | $20.00M 10-K · filed 2025-02-21 | ||||
| 2021-12-31 | $72.00M 10-K · filed 2024-02-23 | ||||
| 2020-12-31 | -$107.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24 | $985.00K derived: sum of 2 quarters · filed 2023-02-24 | $985.00K derived: sum of 3 quarters · filed 2023-02-24 | $17.00M 10-K · filed 2023-02-24 | $17.11M 10-K · filed 2021-02-26 |
| 2020-09-30 | $1.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-30 | $1.09M derived: sum of 2 quarters · filed 2020-10-30 | $17.11M 10-Q · filed 2020-10-30 | $24.28M derived: sum of 4 quarters · filed 2021-02-26 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $16.02M 10-Q · filed 2020-08-06 | $23.19M derived: sum of 3 quarters · filed 2021-02-26 | $32.61M derived: sum of 4 quarters · filed 2021-02-26 | |
| 2020-03-31 | $16.02M 10-Q · filed 2020-05-07 | $23.19M derived: sum of 2 quarters · filed 2021-02-26 | $32.61M derived: sum of 3 quarters · filed 2021-02-26 | $32.61M derived: sum of 4 quarters · filed 2021-02-26 | |
| 2019-12-31 | $7.17M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $16.60M derived: sum of 2 quarters · filed 2021-02-26 | $16.60M derived: sum of 3 quarters · filed 2021-02-26 | $34.01M 10-K · filed 2021-02-26 | |
| 2019-09-30 | $9.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-30 | $9.42M derived: sum of 2 quarters · filed 2020-10-30 | $26.84M 10-Q · filed 2020-10-30 | ||
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $17.42M 10-Q · filed 2020-08-06 | |||
| 2019-03-31 | $17.42M 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |